Honluten N20 – lung peptides

The respiratory system is a collection of structures that allow the capture of oxygen and the removal of carbon dioxide produced by internal respiration. The central organ is the lungs, located on either side of the heart. Lung diseases contribute to the development of pathological processes that lead to a decrease in oxygen in the blood. Which leads to a decrease in lung volume and the development of respiratory failure, leading to disability, significantly reducing the quality of life. In order to normalize and correct pathological changes in the lungs, resulting from various diseases, a bioregulator of the respiratory organ – Honluten was developed.

Honluten is a peptide complex containing amino acids that help normalize the function and cells of the lungs and bronchial mucosa.

Honluten has been clinically studied for its effectiveness in the complex prevention and treatment of patients with lung and bronchial dysfunction in acute and chronic respiratory diseases of infectious and non-infectious origin, as well as for maintenance of respiratory function in elderly and old age.

We found that a course of administration of Honluten in addition to the means of conventional therapy in patients with respiratory failure and lung affection contributed to the improvement of health, reduction of frequency of coughing and choking attacks, reduction of sputum volume, increase of physical performance. There was observed a positive dynamics in the form of reduction of the number of rales and the decrease of the secreted sputum, which reflected the general tendency towards a decrease in inflammatory manifestations of the disease.

Honluten application to athletes of the highest category during the preparation for the competitions permitted to increase the indices of aerobic power and oxygen pulse and increase respiratory reserve. Which led not only to an increase in physical performance compared to the baseline level, but also kept it to the end of the sports season. As a result of studies it was shown that Honluten has the ability to stimulate the functional activity of the main cellular elements of the lung tissue and reduce the level of spontaneous cell death. Thereby the drug has trophic and stabilizing effect on the lung and bronchial tissue and improves its functions.

Honluten is well tolerated by patients and no side effects, complications, contraindications and drug addiction were revealed.

Recommended:

chronic respiratory failure,
chronic cardiopulmonary failure,
after pneumonia,
consequences of prolonged artificial ventilation,
respiratory distress syndrome,
lung tuberculosis in remission,breast trauma,
burns of the upper respiratory tract,
consequences of toxic pulmonary lesions including carbon monoxide poisoning,
intensive sports,
to maintain respiratory function in elderly and senile people.

Composition:

Peptide complex AC-7-(glycine, glutamic acid, asparagic acid). Excipients: microcrystalline cellulose (E460), beet sugar, lactose, starch, tween-80. As an additional source of peptides.

Method of use:

Adults: 1-2 capsules 1-2 times daily with meals. Duration of use: 10-30 days. It is reasonable to repeat the course in 4-6 months.

Formation: 20 capsules of 0.2 g

.